TCRX,TScan Therapeutics, Inc. | Healthcare

Healthcare

TCRX

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

TScan Therapeutics, Inc.TCRX

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer.

It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors.

The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors.

In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease.

TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Latest News >

Ascendis Reports TransCon CNP Shows Durable Benefits in New Data

Mar 16, 2026

10:30 AM EDT, 03/16/2026 (MT Newswires) -- Ascendis Pharma ( ASND ) said Monday new data showed children with achondroplasia treated with TransCon CNP kept consistent growth improvements through week 104, with improvement in body proportionality during the second year of treatment. Two-year data from the ApproaCH Trial demonstrated continued improvement in body proportionality and sustained increases in linear growth,...

Why Is Silvaco Group Stock Gaining Monday?

Mar 16, 2026

Silvaco Group ( SVCO ) shares rose Monday as traders digested the company’s latest quarterly update and forward outlook. Earnings Snapshot The company last week reported fourth-quarter losses of three cents per share, which beat the consensus estimate of a loss of 12 cents. Also, sales of $18.25 million beat the analyst consensus estimate of $16.33 million. Walden Rhines, Silvaco’s Chief Executive Officer, said it secured...

LifeMD Names Atul Kavthekar as CFO

Mar 16, 2026

10:27 AM EDT, 03/16/2026 (MT Newswires) -- LifeMD ( LFMD ) said Monday it has named Atul Kavthekar as its chief financial officer, effective immediately. Kavthekar is replacing Marc Benathen, who is leaving to pursue another opportunity and will remain with LifeMD ( LFMD ) through March 31 to ensure a smooth transition, the company said. LifeMD ( LFMD )...

PennAero Expands Capabilities with Completion of TriMas Aerospace Acquisition

Mar 16, 2026

Combined franchise becomes one of the aerospace industry's leading independent manufacturers of highly engineered fasteners, precision components, and complex assemblies.EL SEGUNDO, Calif., March 16, 2026 /PRNewswire/ -- PennAero today announced the completion of its acquisition of TriMas Corporation's aerospace assets, bringing together two established manufacturers to create a broader, more capable independent supplier for the global aerospace, defense, space, and...